Clinical trial NCT06575452: Using the Epitranscriptome to Diagnose and Treat Gliomas
Official title: Using the Epitranscriptome to Diagnose and Treat Gliomas
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Glioma
Lead sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Sponsor class: OTHER
Collaborators: name: National Cancer Institute, France
First posted: 2024-08-28
Enrollment: 228
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Diffuse gliomas are among the most common tumors of the central nervous system, with high morbidity and mortality and very limited therapeutic possibilities. The diffuse glioma are characterized by significant variability in terms of age at diagnosis, histological and molecular features, classification, ability to transform to a higher grade and/or to disseminate in the brain, response to treatment and patient outcome.

One of the main challenges in the management of diffuse gliomas is related to tumor heterogeneity within the same subgroup. Establishing an accurate tumor classification is of paramount importance for selecting personalized therapy or avoiding unnecessary treatment.

At present, the main diagnostic methods for detecting gliomas are based on histopathological features and mutation detection. Yet difficulties remain, due to tumor heterogeneity and sampling bias for tumors obtained from small biopsies. In particular, grade 2 (low-grade) and grade 3 (high-grade) gliomas cannot be easily distinguished, as intra-tumoral tumor grade heterogeneity is not uncommon in patients treated with extensive surgical resection. Another challenge in the field of gliomas is longitudinal monitoring of disease progression, which is currently mainly based on repeated brain Magnetic Resonance Imaging (MRI). New tools to detect tumor changes before the onset of imaging changes would be useful.

Several genetic, epigenetic, metabolic and immunological profiles have been established for gliomas. Recently, the world of RiboNucleic Acid (RNA) has emerged as a promising area to explore for cancer therapy, especially since the (re)discovery of RNA chemical modifications. To date, more than 150 types of post-transcriptional modifications have been reported on various RNA molecules. This complex landscape of chemical marks embodies a new, invisible code that governs the post-transcriptional fate of RNA: stability, splicing, storage, translation.

Detailed description: Diffuse gliomas are among the most common tumors of the central nervous system, with high morbidity and mortality and very limited therapeutic possibilities. Diffuse gliomas are characterized by great variability in terms of age at diagnosis, histological and molecular features, classification, ability to progress to a higher grade and/or to disseminate in the brain, response to treatment and patient outcome. One of the major challenges in the management of diffuse gliomas is related to the heterogeneity of tumor behavior within the same tumor subgroup. Although efforts have been made in recent decades to improve tumor characterization and classification, with the integration of molecular markers (e.g. Isocitrate DeHydrogenase (IDH) mutation), it remains difficult to predict treatment response and patient outcome at the individual level. Yet accurate tumor classification is of paramount importance in choosing personalized therapy or avoiding unnecessary treatments. At present, the main diagnostic methods for detecting gliomas are based on histopathological features, mutation detection or chromosome copy number variation.

However, difficulties remain, particularly with tumor classification, due to tumor heterogeneity and sampling bias for tumors obtained from small biopsies. In particular, grade 2 ("low-grade") and grade 3 ("high-grade") gliomas cannot be easily distinguished, as intratumoral tumor grade heterogeneity is not uncommon in patients treated with extensive surgical resection. Another challenge posed by gliomas is longitudinal monitoring of disease progression, which currently relies mainly on repeated brain MRI scans, with no return to the tumor itself due to the difficulty of obtaining new tumor samples in this setting. New tools to detect tumor changes in plasma, before imaging changes occur, would be useful. However, circulating markers present a real challenge, as the detection of markers readily used in other cancer types (e.g. circulating free DNA and circulating tumor cells) is hampered by a lack of sensitivity in gliomas.

Several genetic, epigenetic, metabolic and immunological profiles have been established in gliomas, considerably expanding the knowledge of the biological characteristics of these tumors and helping to identify potential treatments. Recently, the world of RNA has emerged as a promising area to explore for cancer therapy, particularly since the (re)discovery of chemical modifications of RNA (epitranscriptomics). To date, over 150 types of post-transcriptional modification have been reported on various RNA molecules. This landscape complex of chemical marks embodies a new, invisible code that governs the post-transcriptional fate of RNA: stability, splicing, storage, translation. Importantly, RNA epigenetics has emerged as a new layer of gene expression regulation in healthy tissues as well as in other pathologies such as cancer.

Chemical markers are associated with cancer evolution and adaptation, as well as with response to conventional therapies. Based on these observations, it is envisaged that: (1) the RNA epigenetic landscape evolves with cancer progression, establishing a "chemical signature" that could be exploited for diagnostic, prognostic and treatment response prediction purposes; (2) several chemical marks are not mere "transient" alterations but rather "driving" alterations of the tumorigenic process; (3) unlike unmodified nucleosides, modified nucleosides are preferentially excreted as metabolic end products in urine after circulating in the blood. Consequently, altered RNA markers in cancerous tissues can be detected in urine and blood and exploited for diagnostic purposes. An original approach recently published combines multiplex analysis of RNA marks by mass spectrometry with bioinformatics and machine learning. Using total RNA samples extracted from an existing cohort of patients (59 grade 2, 3 and 4 gliomas; 19 non-cancerous control samples), a first "chemical signature" capable of predicting glioma grade with remarkable efficiency and accuracy has been established.

N6, 2'-O-dimethyladenosine (m6Am), the most up-regulated marker in glioblastoma (GBM), is a driver of colorectal cancer aggressiveness. Located at the 5' end of messenger RiboNucleic Acid (mRNA), m6Am can influence mRNA stability and translation efficiency. This chemical tag is deposited by the Phosphorylated Carboxyl terminal domain Interacting Factor 1 (PCIF1), also known as CAPAM (PCIF1/CAPAM) methyltransferase (writer) and removed by the Fat mass and Obesity-associated protein (FTO) demethylase (eraser). FTO is down-regulated in colorectal cancer stem cells (CSCs), consistent with m6Am accumulation. High levels of m6Am significantly enhance CSC properties such as in vivo tumor initiation and chemoresistance, without significant changes to the transcriptome. This aggressive phenotype can be reversed by inhibition of PCIF1, demonstrating the potential of targeting epigenetic RNA effectors. The preliminary data on patient-derived glioma cell lines suggest a similar mechanism in glioma, where down-regulation of FTO promotes sphere-forming capacity in suspension culture of GBM stem cells.

(3) A method has been established to detect RNA markers in plasma samples that yielded favorable results after analysis of plasma samples from a colorectal cancer cohort. The same process was used to obtain preliminary data by analyzing plasma samples from grade 2 glioma patients vs. healthy donors. This experiment confirmed the possibility of detecting and quantifying 20 circulating nucleosides in blood. Significant changes were demonstrated between healthy donors and glioma patient samples for some of the circulating nucleosides. Some were up-regulated (e.g. n6,2'-O-dimethyladenosine (m6Am), 1-methylguanosine (m1G)) while others were down-regulated (e.g. adenosine (A), 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U)). Importantly, not all the tagged RNAs detected were altered (e.g. N1-methyladenosine (m1A); 5-methylcytosine (m5C)). If confirmed by a larger cohort, these changes could constitute an epitranscriptomics-based circulating signature for early disease detection. This preliminary experience reinforces the interest in m6Am.

Finally, changes were also observed in the serum of the same patients compared to healthy donor subjects, but from other nucleosides. This underlines the importance of studying circulating markers in blood for the diagnosis of gliomas.

Eligibility criteria: Inclusion Criteria:

* Male / female over 18 years of age,
* Surgery (tumor resection) scheduled at Montpellier University Hospital for suspected, diffuse glioma, confirmed on tissue sample: IDH mutated grade 2 glioma (excluding tumors with a focus of grade 3 or 4 glioma), IDH mutated grade 3 glioma or GBM, IDH wild-type,
* No history of treatment (surgery, radiotherapy or chemotherapy) for glioma,
* Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures,
* Patient has given express written informed consent prior to any study procedure,
* Patient affiliated to a French health insurance.

Exclusion Criteria:

* Patients whose regular follow-up is impossible for psychological, family, social or geographical reasons,
* Patients under guardianship, curatorship or safeguard of justice,
* Pregnant and/or breast-feeding patient (information gathered from the medical file, as part of the patient's standard medical care and follow-up),
* Histo-molecular diagnosis of grade 4 IDH-mutated astrocytoma,
* For grade 2 gliomas, presence within the tumor of one or more higher-grade sites (3 or 4).

Primary outcomes:
measure: Sensitivity of RNA-modified nucleoside expression marks for glioma diagnosis vs controls in blood for patients in cohort 1.
timeFrame: At baseline, 3 months, 9 months and 18 months
measure: Specificity of RNA-modified nucleoside expression marks for glioma diagnosis vs controls in blood for patients in cohort 1.
timeFrame: At baseline, 3 months, 9 months and 18 months
measure: Positive Predictive Value (PPV) of modified nucleoside expression marks for the diagnosis of glioma vs. controls in blood for patients in cohort 1.
timeFrame: At baseline, 3 months, 9 months and 18 months
measure: Negative Predictive Value (NPV) of modified nucleoside expression marks for the diagnosis of glioma vs. controls in blood for patients in cohort 1.
timeFrame: At baseline, 3 months, 9 months and 18 months
Secondary outcomes:
measure: Sensitivity of RNA-modified nucleoside expression marks for glioma diagnosis vs controls in urine for patients in cohort 1.
timeFrame: At baseline, 3 months, 9 months and 18 months
measure: Specificity of RNA-modified nucleoside expression marks for glioma diagnosis vs controls in urine for patients in cohort 1.
timeFrame: At baseline, 3 months, 9 months and 18 months
measure: Positive Predictive Value (PPV) of modified nucleoside expression marks for the diagnosis of glioma vs. controls in urine for patients in cohort 1.
timeFrame: At baseline, 3 months, 9 months and 18 months
measure: Negative Predictive Value (NPV) of modified nucleoside expression marks for the diagnosis of glioma vs. controls in urine for patients in cohort 1.
timeFrame: At baseline, 3 months, 9 months and 18 months
measure: Progression-free survival
timeFrame: Time from histological diagnosis to date of progression according to the Response Assessment in Neuro-Oncology Criteria (RANO 2.0) or death from any cause, assessed up to 18 months.
measure: Global survival
timeFrame: Time from histological diagnosis to the date of death, whatever the cause, assessed up to 18 months.
measure: The best response according to RANO 2.0
timeFrame: Time from surgery to magnetic response imagery (MRI) showing best response, assessed up to 18 months.
measure: Quantitative value obtained by Liquid Chromatography-Mass Spectrometry (LC-MS) for each post-transcriptional modification (mark) of RiboNucleic Acid (RNA) in cohort 3
timeFrame: At baseline, 3 months, 9 months and 18 months
measure: Immunohistochemical detection of the Alpha-thalassemia-X-linked intellectual disability (ATRX) protein
timeFrame: At surgery, Day 0
measure: Tumor grading and classification
timeFrame: At surgery, Day 0
measure: Immunohistochemical detection of kiel 67 (KI67) protein
timeFrame: At surgery, Day 0 of our timeline
measure: Sensitivity of RNA-modified nucleoside expression marks for glioma diagnosis vs controls in tumoral tissue for patients in cohort 1 and 2.
timeFrame: At Surgery, day 0 of our timeline
measure: Specificity of RNA-modified nucleoside expression marks for glioma diagnosis vs controls in tumoral tissue for patients in cohort 1 and 2.
timeFrame: At Surgery, day 0 of our timeline
measure: Positive Predictive Value (PPV) of modified nucleoside expression marks for the diagnosis of glioma vs. controls in tumoral tissue for patients in cohort 1 and 2.
timeFrame: At surgery, day 0 of our timeline
measure: Immunohistochemical detection of the isocitrate DeHydorgenase (IDH) mutated protein
timeFrame: At surgery, Day 0 of our timeline
measure: Measurement of mean tumor diameter (MTD) spontaneous growth rate by magnetic resoance imaging (MRI)
timeFrame: Assessed during follow-up, up to 18 months
measure: Determination of the quality of surgical resection by magnetic resonance imaging (MRI)
timeFrame: After surgery, approximately 30 days
measure: Determination of tumor volume in cm3 by magnetic resonance imaging
timeFrame: At baseline and during follow-up, assessed up to 18 months
measure: Magnetic resonance imaging (MRI) evaluation of tumor invasion of soft meninges (leptomeningeal)
timeFrame: At baseline
measure: Magnetic resonance imaging (MRI) determination of the number of tumor foci in the brain
timeFrame: At baseline
measure: Existence of contrast (gadolinium) zone determined on magnetic resonance imaging (MRI)
timeFrame: At baseline
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Insitut Régional du Cancer de Montpellier
state: Hérault
city: Montpellier
country: France
facility: CHU Montpellier - Hôpital St Eloi
Study officials:
affiliation: Institut régional du Cancer de Montpellier (ICM)
name: Amélie DARLIX, MD
role: STUDY_CHAIR
References:
citation: Jonkhout N, Tran J, Smith MA, Schonrock N, Mattick JS, Novoa EM. The RNA modification landscape in human disease. RNA. 2017 Dec;23(12):1754-1769. doi: 10.1261/rna.063503.117. Epub 2017 Aug 30.
citation: Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9.
citation: Posti JP, Bori M, Kauko T, Sankinen M, Nordberg J, Rahi M, Frantzen J, Vuorinen V, Sipila JO. Presenting symptoms of glioma in adults. Acta Neurol Scand. 2015 Feb;131(2):88-93. doi: 10.1111/ane.12285. Epub 2014 Sep 28.
citation: Darlix A, Rigau V, Fraisse J, Goze C, Fabbro M, Duffau H. Postoperative follow-up for selected diffuse low-grade gliomas with WHO grade III/IV foci. Neurology. 2020 Feb 25;94(8):e830-e841. doi: 10.1212/WNL.0000000000008877. Epub 2020 Jan 22.
citation: Pedeutour-Braccini Z, Burel-Vandenbos F, Goze C, Roger C, Bazin A, Costes-Martineau V, Duffau H, Rigau V. Microfoci of malignant progression in diffuse low-grade gliomas: towards the creation of an intermediate grade in glioma classification? Virchows Arch. 2015 Apr;466(4):433-44. doi: 10.1007/s00428-014-1712-5. Epub 2015 Jan 21.
citation: Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020 Jun;20(6):303-322. doi: 10.1038/s41568-020-0253-2. Epub 2020 Apr 16.
citation: Macari F, El-Houfi Y, Boldina G, Xu H, Khoury-Hanna S, Ollier J, Yazdani L, Zheng G, Bieche I, Legrand N, Paulet D, Durrieu S, Bystrom A, Delbecq S, Lapeyre B, Bauchet L, Pannequin J, Hollande F, Pan T, Teichmann M, Vagner S, David A, Choquet A, Joubert D. TRM6/61 connects PKCalpha with translational control through tRNAi(Met) stabilization: impact on tumorigenesis. Oncogene. 2016 Apr 7;35(14):1785-96. doi: 10.1038/onc.2015.244. Epub 2015 Aug 3.
citation: Relier S, Amalric A, Attina A, Koumare IB, Rigau V, Burel Vandenbos F, Fontaine D, Baroncini M, Hugnot JP, Duffau H, Bauchet L, Hirtz C, Rivals E, David A. Multivariate Analysis of RNA Chemistry Marks Uncovers Epitranscriptomics-Based Biomarker Signature for Adult Diffuse Glioma Diagnostics. Anal Chem. 2022 Sep 6;94(35):11967-11972. doi: 10.1021/acs.analchem.2c01526. Epub 2022 Aug 23.
citation: Relier S, Ripoll J, Guillorit H, Amalric A, Achour C, Boissiere F, Vialaret J, Attina A, Debart F, Choquet A, Macari F, Marchand V, Motorin Y, Samalin E, Vasseur JJ, Pannequin J, Aguilo F, Lopez-Crapez E, Hirtz C, Rivals E, Bastide A, David A. FTO-mediated cytoplasmic m6Am demethylation adjusts stem-like properties in colorectal cancer cell. Nat Commun. 2021 Mar 19;12(1):1716. doi: 10.1038/s41467-021-21758-4.
citation: Amalric A, Bastide A, Attina A, Choquet A, Vialaret J, Lehmann S, David A, Hirtz C. Quantifying RNA modifications by mass spectrometry: a novel source of biomarkers in oncology. Crit Rev Clin Lab Sci. 2022 Jan;59(1):1-18. doi: 10.1080/10408363.2021.1958743. Epub 2021 Sep 2.
citation: Wen PY, van den Bent M, Youssef G, Cloughesy TF, Ellingson BM, Weller M, Galanis E, Barboriak DP, de Groot J, Gilbert MR, Huang R, Lassman AB, Mehta M, Molinaro AM, Preusser M, Rahman R, Shankar LK, Stupp R, Villanueva-Meyer JE, Wick W, Macdonald DR, Reardon DA, Vogelbaum MA, Chang SM. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol. 2023 Nov 20;41(33):5187-5199. doi: 10.1200/JCO.23.01059. Epub 2023 Sep 29.
citation: Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, Vickers AJ, Ransohoff DF, Collins GS. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015 Jan 6;162(1):W1-73. doi: 10.7326/M14-0698.
citation: Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986 Feb 8;1(8476):307-10.